Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 1998
Business Overview: The company manufactures medical devices, including custom kits, syringes, manifolds, needles, and guide wires. It operates domestic and international facilities, including a subsidiary in Ireland (Sentir) and manufacturing operations in Castlerea, Ireland.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1998 |
Six Months Ended June 30, 1998 |
|---|---|---|
| Sales (Revenue) | $17,974,170 | $34,440,185 |
| Gross Profit | $6,812,741 | $12,975,902 |
| Gross Margin | 37.9% | 37.7% |
| Operating Income | $1,382,228 | $2,490,231 |
| Net Income | $586,558 | $1,014,213 |
| Earnings Per Share (Basic/Diluted) | $0.08 | $0.14 |
| Cash from Operations (6mo) | $1,480,851 | |
| Working Capital | $14,760,003 (Current Assets $27.9M - Current Liab. $13.2M) | |
| Current Ratio | 2.1 to 1 | |
| Line of Credit Outstanding | $5,236,337 (of $10.5M available) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 17% for the quarter and 18% for the six-month period compared to 1997. Custom kit business grew 24%, while other devices grew 14%. OEM sales surged 90% in the first half of 1998.
- Profitability: Net income more than doubled for the quarter (up from $283,960 to $586,558) and the six-month period (up from $476,027 to $1,014,213). Operating income increased significantly due to higher sales and reduced R&D expenses.
- Margins: Gross margin declined slightly to 37.9% (Q2) and 37.7% (6mo) from 38.5% and 38.7% in 1997, attributed to price competition in Europe and a strong U.S. dollar. However, this represents the fourth consecutive quarter of margin improvement.
- Expenses: Operating expenses as a percentage of sales decreased to 30.2% (Q2) from 33.2% (prior year Q2). R&D expenses dropped to 4.8% of sales due to the completion of the Tomcat guide wire project.
- Cash Flow: Net cash provided by operating activities improved dramatically to $1.48 million for the six months ended June 30, 1998, compared to only $35,686 in the same period in 1997.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current sources of liquidity (cash, line of credit, equity sales) are adequate for current operations. The company maintains a $10.5 million secured bank line of credit.
- Capital Expenditures: Significant capital was used for property and equipment ($1.8 million in the first half of 1998) to support growth. The company sold its Castlerea, Ireland facility in April 1998, receiving approximately $520,000 in cash and having the buyer assume the land/building note.
- Market Risks: The company faces risks from foreign currency fluctuations (specifically the strong U.S. dollar impacting European sales) and interest rate risk on variable-rate debt. No hedging agreements are currently in place.
- Year 2000 Compliance: The company is converting to a new integrated software system to ensure Year 2000 compliance without material additional expenditures. Risks remain regarding third-party vendors and customers.
- Forward-Looking Statements: Actual results may differ due to product acceptance, recalls, competition, and regulatory environments.
Investor Verification Checklist
- Verify the sustainability of the 90% growth in OEM sales and whether this is a one-time event or a recurring trend.
- Monitor the impact of the strong U.S. dollar on future gross margins, particularly for European sales which accounted for 23% of revenue.
- Confirm the status of the new integrated software system conversion and its impact on Year 2000 readiness.
- Review the utilization of the $10.5 million line of credit, currently at $5.2 million, to assess future borrowing capacity.
- Assess the long-term impact of the sale of the Irish facility on manufacturing capacity and future expansion plans.